부산대학교 도서관

As docetaxel is known to have significant antineoplastic activity against breast and ovarian cancer, we explored its application as a peripheral blood stem cell mobilizing agent in 33 women with stage lll–IV ovarian carcinoma (n = 10) or stage ll–lV breast cancer (n = 23) who were in preparation for high-dose chemotherapy. Eleven patients had bone and/or bone marrow involvement with their disease. The median number of prior regimens received before mobilization was two (range 1–3). The three dose levels administered were 100 mg/m2, 110 mg/m2 and 120 mg/m2. Patients received one dose of docetaxel in the outpatient setting followed by G-CSF (10 μg/kg/day) starting 4 days after docetaxel administration. Leukapheresis commenced when WBC >1.0 × 109/l or when the WBC began to rise after reaching a nadir. Ninety-seven percent of patients began leukapheresis within 7–9 days after receiving docetaxel (range 7–10 days). The collection goal was 2 × 106 CD34+ cells/kg. Twenty-seven (82%) patients reached this goal in a median of 2 leukapheresis days (range 1–3). No grade 2–4 nonhematologic toxicities were noted. Thirteen patients (55%) showed a WBC nadir >1.0 × 109/l. None of the patients experienced neutropenic fever or required blood or platelet transfusion support. In conclusion, docetaxel + G-CSF is an effective, well-tolerated regimen for PBPC mobilization which can be safely administered in the outpatient setting with minimal toxicity. Bone Marrow Transplantation (2001) 27, 677–681. [ABSTRACT FROM AUTHOR]